BB50248: Cancer genetics and therapy
[Page last updated: 02 August 2022]
Academic Year: | 2022/23 |
Owning Department/School: | Department of Biology & Biochemistry |
Credits: | 15 [equivalent to 30 CATS credits] |
Notional Study Hours: | 300 |
Level: | Masters UG & PG (FHEQ level 7) |
Period: |
|
Assessment Summary: | CW 50%, EX 50% |
Assessment Detail: |
|
Supplementary Assessment: |
|
Requisites: | |
Learning Outcomes: | By the end of this unit you will be able to:
* Apply broad knowledge gained from current literature to compare the molecular and micro-environmental differences of cancer and normal tissues * Demonstrate an integrative and critically evaluative approach to analyse how these differences are exploited in drug design for conventional and rationalised cancer therapies * Critically evaluate and communicate the findings from cutting-edge research publications in cancer genetics and therapy through formal presentation. |
Aims: | The unit aims to provide students knowledge of contemporary cancer research and the challenges and opportunities in developing treatments for cancer. |
Content: | Topics include the genetic hallmarks of cancer development including oncogenesis (oncogenes/tumour suppressor genes/viral oncogenesis), angiogenesis, metastasis, metabolic reprogramming, cancer stem cell niches. This will be followed by exploration of the latest research in treatments for cancer, including conventional (radio/chemotherapy) and rationalised treatments, such as immunotherapies etc. |
Programme availability: |
BB50248 is Optional (DEU) on the following programmes:Department of Biology & Biochemistry
|
Notes:
|